Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

By Carsten Denkert, G. von Minckwitz, J. C. Brase, Bruno Sinn, Stephan Gade, R. Kronenwett, B. Pfitzner, C. Salat, S. Loi, W. Schmitt and 20 more. Journal of Clinical Oncology, 2015

942 citations recorded by the source corpus.

Subfields: Cancer Research, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/37c1bee8da289b8c77925941a58fd99a1f19fe43

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. L. Galluzzi
2. Guido Kroemer
3. L. Zitvogel
4. H. Moses

In Immunology

1. Guido Kroemer
2. L. Galluzzi
3. L. Zitvogel
4. Oliver Kepp
5. A. Buqué
6. H. Moses
7. M. Smyth
8. V. Schirrmacher

In Oncology

1. Guido Kroemer
2. L. Galluzzi
3. L. Zitvogel
4. Oliver Kepp
5. H. Moses
6. R. Weinberg
7. Rebecca S. Y. Wong

Citations in the corpus

• Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection (2016, background): “Recent studies have suggested prognostic value of TILs in TNBC[23,24].”
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “…of TILs correlated with low grade Tsang et al., 2014 HE breast carcinoma neoadjuvant chemotherapy increased levels of stromal TILs predicted pCR Denkert et al., 2015 ductal breast carcinoma adjuvant multimodal chemotherapy high levels of TILs correlated with improved TTR and OS Mohammed et…”
• IDO in the Tumor Microenvironment: Inflammation, Counter-regulation and Tolerance (2016, neutral): “, associated with increased T cell infiltration and inflammation [37, 54, 55].”
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, background): “An improved pCR rate was also observed in triple-negative breast cancer using nab-paclitaxel instead of solvent-based paclitaxel [50]. pCR rates were higher in patients with lymphocyte predominant breast cancer, either triple-negative or HER2-positive, who were treated with carboplatin [77].”
• Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study (2019, neutral): “(%) [95% CI] 5 (24) [8-47] 10 (11) [5-19] 0 [0-17] 15 (16) [10-26]”